European Biotech Acquisition Accounts Payable

The latest accounts payable for EBAC is $360K as of December 2022. That compares with $58K in the prior-year period — up 520.9% year over year. Investors often review this figure alongside European Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBAC's accounts payable moved from $58K to $360K — a 520.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition's operating scale or balance-sheet position.

A accounts payable figure of $360K for EBAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBAC's accounts payable ($360K), review year-over-year change from $58K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.